1. Home
  2. VYGR vs ASMB Comparison

VYGR vs ASMB Comparison

Compare VYGR & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VYGR
  • ASMB
  • Stock Information
  • Founded
  • VYGR 2013
  • ASMB 2005
  • Country
  • VYGR United States
  • ASMB United States
  • Employees
  • VYGR N/A
  • ASMB N/A
  • Industry
  • VYGR Biotechnology: Pharmaceutical Preparations
  • ASMB Biotechnology: Pharmaceutical Preparations
  • Sector
  • VYGR Health Care
  • ASMB Health Care
  • Exchange
  • VYGR Nasdaq
  • ASMB Nasdaq
  • Market Cap
  • VYGR 231.9M
  • ASMB 196.9M
  • IPO Year
  • VYGR 2015
  • ASMB 2010
  • Fundamental
  • Price
  • VYGR $4.95
  • ASMB $29.45
  • Analyst Decision
  • VYGR Strong Buy
  • ASMB Strong Buy
  • Analyst Count
  • VYGR 8
  • ASMB 5
  • Target Price
  • VYGR $16.71
  • ASMB $44.25
  • AVG Volume (30 Days)
  • VYGR 814.4K
  • ASMB 154.9K
  • Earning Date
  • VYGR 11-11-2025
  • ASMB 11-06-2025
  • Dividend Yield
  • VYGR N/A
  • ASMB N/A
  • EPS Growth
  • VYGR N/A
  • ASMB N/A
  • EPS
  • VYGR N/A
  • ASMB N/A
  • Revenue
  • VYGR $42,580,000.00
  • ASMB $33,247,000.00
  • Revenue This Year
  • VYGR N/A
  • ASMB $14.32
  • Revenue Next Year
  • VYGR $107.10
  • ASMB N/A
  • P/E Ratio
  • VYGR N/A
  • ASMB N/A
  • Revenue Growth
  • VYGR N/A
  • ASMB 54.77
  • 52 Week Low
  • VYGR $2.65
  • ASMB $7.75
  • 52 Week High
  • VYGR $8.28
  • ASMB $30.20
  • Technical
  • Relative Strength Index (RSI)
  • VYGR 58.14
  • ASMB 70.92
  • Support Level
  • VYGR $4.72
  • ASMB $23.21
  • Resistance Level
  • VYGR $5.55
  • ASMB $29.20
  • Average True Range (ATR)
  • VYGR 0.35
  • ASMB 1.68
  • MACD
  • VYGR -0.01
  • ASMB 0.46
  • Stochastic Oscillator
  • VYGR 54.88
  • ASMB 92.59

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

Share on Social Networks: